Communication and Technology

Individual

In the Fall of 2020, I gave a presentation on my literature review paper for my MB 585 course. It pertained to RNAi use for crop protection in three row crops: wheat, soybean, and canola. RNAi has recently been presented as a possible alternative to pesticides and fungicides in the crop protection industry.

In the Spring of 2021, I gave a presentation on my literature review paper for my MB 585 course. It pertained to non-transformative RNAi use for control of the fungal pathogen Sclerotinia sclerotiorum. RNAi has recently been presented as a possible alternative to fungicides in the crop protection industry.

In the Spring of 2021, I wrote a literature review paper for my MB 585 course. It pertained to non-transformative RNAi use for control of the fungal pathogen Sclerotinia sclerotiorum. RNAi has recently been presented as a possible alternative to fungicides in the crop protection industry.

Teamwork

In the Fall of 2020, my MB 585 group and I gave a presentation related to our CMI project. Our project was related to the use of a novel therapeutic, BIO-PLY, used to treat osteoarthritis in horses. We performed a market analysis as well as research into alternative markets.

In the Fall of 2020, my MB 585 group and I gave a final presentation for our practicum project with BASF related to RNAi use for crop protection. We worked as a group to compile market information related to our crops and to determine pest and disease targets within those crops.

In the Spring of 2021, my MB 585 group and I gave a final presentation for our practicum project with Panaceutics which involved identifying potential partnership opportunities. We worked as a group to compile market information related to personalized nutrition and to determine companies to target with pitch strategies.

In the Spring of 2021, my MBA 585 group wrote a final report related to new trends in biopharmaceuticals. We worked as a group to compile market information related to the biopharmaceutical market, detail the history of biologics, and provide regulatory information related to biologics and biosimilars.